Company ProfilePremium

Holista CollTech Limited

Company Profile Analysis

Ticker: HCT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Holista CollTech Limited - Company showcase

Year Founded & Workforce

1995

Holista CollTech Limited logo

Holista CollTech Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Holista CollTech Limited Overview

Holista Colltech is a Perth-domiciled, Malaysia-operated natural health company whose economic engine is a mature, cash-generative dietary supplements franchise in Malaysia — anchored by the halal-certified PRISTIN® Omega-3 fish oil brand — wrapped around a portfolio of long-dated technology options. The options include patented ovine (sheep-derived) collagen and nano-collagen, which management positions as the world's only collagen extracted from disease-free Australian sheep using patented methods; low-glycaemic-index food ingredient technologies (low-GI bread, noodles, flatbreads and a sugar substitute); natural sanitisers; and an embryonic agricultural biotechnology line (nano urea, nano copper, poultry probiotics). Supplements generated 90.6% of FY2025 revenue and Malaysia 97.4%, so the investment case is effectively a small Malaysian consumer health distributor carrying ASX listing costs, legacy litigation scars (ASIC penalty, ProImmune judgment) and an optionality layer whose value hinges on the Regenerex wound-care supply agreement and the Ovicoll collagen joint venture in Collie, Western Australia.


Company's own description (paraphrased from FY2025 Annual Report)

Holista describes itself as a research-driven biotech company formed from the merger of Holista Biotech Sdn Bhd and Colltech Australia Ltd, headquartered in Perth and operating primarily in Australia and Malaysia. Its stated core purpose is to research natural solutions that help people live healthier lives. The company highlights four strands: (i) proprietary food-ingredient solutions that allow manufacturers to make healthier products without chemicals and without compromising taste, odour or mouthfeel — commercialised to date as low-GI bread, noodles/pasta, flatbreads and a low-calorie/low-GI sugar substitute; (ii) ovine collagen, where it claims to be the only producer globally using disease-free Australian sheep and patented extraction methods; (iii) leadership in Malaysian distribution of natural health supplements; and (iv) a range of all-natural, non-toxic sanitisers for consumer and industrial use (FY2025 Annual Report, "About Us" and "Corporate Profile").

The principal activities listed in the FY2025 Directors' Report are the manufacture and sale of "health-style" products across Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture.

Independent characterisation

Stripped of its biotech framing, Holista in FY2025 is a branded consumer health distributor in Malaysia with an attached technology-licensing ambition. Three facts dominate the economics:

  1. Product concentration. Supplements generated A$5.22m of A$5.76m FY2025 revenue (90.6%) and A$0.77m segment profit before tax, while all other operating segments combined generated A$0.54m of revenue (FY2025 Annual Report Note 3).

  2. Channel concentration. Within Supplements, one single external distributor accounted for 92% of segment revenue in FY2025 (91% in FY2024), which equates to roughly 83% of group revenue. Food Ingredients relies on a few customers for 85% of segment revenue, and Ovine Collagen relies on one customer for 100% (FY2025 Annual Report Note 3, "Major customers").

  3. Geographic concentration. Malaysia contributed A$5.62m (97.4%) of FY2025 revenue; Australia A$0.15m (2.6%), all from ovine collagen; the United States recorded no external revenue (FY2025 Annual Report Note 4).

Business and revenue model

DimensionCharacterisationEvidence
Revenue model mix~100% product sales recognised at a point in time; royalty income is a disclosed accounting policy, but no material royalty revenue was reported in FY2025FY2025 Annual Report Note 4 ("Goods transferred at a point in time: 5,764,055")
Product vs service vs subscription vs licensingProduct: ~100%. Service: nil. Subscription: nil. Licensing: nil reported (Regenerex agreement structured as supply with exclusivity; Ovicoll JV to pay an 8% royalty to Holista from future JV sales)FY2025 Annual Report; JV announcement 5 May 2026
Value chain positionSupplements: brand owner and marketer using contract manufacturing and third-party distribution (fish oil sourced from South America, processed in Norway, per 2021 management commentary). Collagen: vertically integrated extractor (legacy Collie plant, now being replaced via JV). Food ingredients: B2B formulator/supplierFY2025 Annual Report; NutraIngredients-Asia, April 2021
Customer typesMalaysian pharmacy retail via a master distributor; Holista-owned webstores (Alterni.com, Holista.global per September 2025 announcement); B2B food and beverage manufacturers; one B2B collagen customer; US wound-care partner (Regenerex); agricultural customers in Malaysia (pilot stage)FY2025 Annual Report; ASX announcement 11 September 2025
End-marketsConsumer health supplements (Malaysia); food ingredients (Malaysia/ASEAN); cosmetic-grade collagen (export); medical wound care (US, pre-commercial); agriculture (Malaysia, pilot)FY2025 Annual Report

Revenue recognition includes rights of return and volume rebates. At 31 December 2025, right-of-return assets were A$339,437 and refund liabilities were material (A$862,592 at 30 June 2025). FY2024 revenue was depressed by returns from a major chain pharmacy, so returns accounting is a live earnings-quality consideration (FY2024 Appendix 4E; 1H FY2025 Interim Report Note 7).

Strategy

Stated strategy (FY2025 Annual Report, paraphrased)

The Chairman characterises FY2025 as a year of financial stabilisation, balance-sheet repair and strategic reset under new leadership. Management's stated priorities are operational discipline, cost management and prudent capital allocation, alongside developing new commercial applications for the group's technologies. The 1H FY2025 review added digital marketing and a strategic shift toward high-value pharmaceutical collagen applications.

Initiatives (last 24 months)

InitiativeDateDescriptionStatus / targetSource
Regenerex wound-care supply agreement26 Aug 2025Exclusive worldwide wound-care rights to Holista's ovine and nano-collagen; Regenerex funds clinical trials and FDA approvals; co-development with shared IPFirst order US$51,700 (24 Dec 2025). Minimum purchases: US$3m (2026), US$6m (2027), US$9m p.a. from 2028. No penalty for shortfall other than Holista's termination right1H FY2025 Interim Report Note 1; Appendix 4C Jan 2026
Ovicoll JV (Collie)5 May 202650:50 JV with Swang Chai Chuan (HKEX: 2321); SCC contributes RM5m (~A$1.6m); Holista manages operations; Holista option to move to 75% over five years; JV pays Holista an 8% royalty on gross sales, capped at 20% of JV pre-tax profit; Holista retains IPLand acquired June 2026; operations targeted December 2026 (FY2025 Annual Report said 2H 2026, subject to funding)ASX announcements 5 May and 19 Jun 2026; Antara/ACN Newswire
Collagen manufacturing consolidation in AustraliaFY2025Replace closed Collie plant with an asset-light modular facility incorporating nano-element capability; Sarawak plan droppedIn progress via OvicollFY2025 Annual Report
Agricultural biotechnologyFY2025 onwardNano urea, nano copper, poultry probiotics in MalaysiaA$9,410 revenue FY2025; A$23,484 in 1H FY2026FY2025 Annual Report; 1H FY2026
Odour management solutions2,026New product lineInitial revenue "may" be recorded in 2026FY2025 Annual Report
Digital and marketplace expansion (Supplements)2025–2026Expanded online marketplace presence and stronger sales teamSupplements +12.2% in 1H FY20261H FY2026 Half Year Review
Anti-counterfeit action11 Sep 2025Police report over counterfeit PRISTIN sold on e-commerce platforms; engagement with regulators and the Malaysian Muslim Consumer AssociationOngoingASX announcement
Capital managementMar 2025 – Jul 2026A$1.55m convertible notes; A$2.295m placement; A$370,724 Powerwind convertible loanCompletedFY2025 Annual Report; ASX announcements
ESG / sustainability commitments—No quantified commitments disclosed——
Cost programmes with targets—Qualitative cost discipline only; no numerical targets——

Medium-term targets and guidance

No formal financial guidance has been issued. The only quantified forward figures are the Regenerex minimum purchase commitments. These are not guaranteed: there is no financial penalty if Regenerex falls short, and the company itself flags the risk to its cash flow projections (1H FY2025 Interim Report, going concern note). Against a 2026 minimum of US$3m, Ovine Collagen interim revenue in 1H FY2026 appears immaterial. The 2026 commitment is therefore at high risk of not being met in calendar 2026.

Products & Services

Pricing is generally not disclosed in filings. Where third-party retail prices are cited, they are labelled.

Supplements

Product / brandDescription & capabilitiesTarget customerLaunch / latestPricingSource
PRISTIN® Omega-3 Fish Oil 1200mg softgelHalal-certified Omega-3 (EPA/DHA) fish oil; flagship product; sold through MOH-licensed pharmaciesMalaysian adult consumers, including Muslim consumersLong-standing (pre-2012)2021 retail price RM67.60 per 30 capsules, cited by trade press as the most expensive in MalaysiaASX announcement 11 Sep 2025; NutraIngredients-Asia, Apr 2021
PRISTIN® GOLD Omega-3 Fish Oil 1200mg softgelPremium variant of the flagship lineSame——ASX announcement 11 Sep 2025
PRISTIN® MOPL (Marine Omega Phospholipids)Third-generation herring-roe phospholipid Omega-3 (650mg Omega-3 per gel), claimed to have higher absorptionPremium consumersc.2015 launch (date approximate)—The Edge Malaysia; NutraIngredients-Asia
PRISTIN® Omega-3 gummies (kids)Children's Omega-3 gummyParents and childrenPlanned 2Q 2021—NutraIngredients-Asia, May 2021
SKNPRO CollagenCollagen beauty supplementConsumersLaunched FY2024—FY2024 Appendix 4E
PROBIO-30Probiotic supplementConsumersLaunched FY2024—FY2024 Appendix 4E
Omega-3 (new registration)Omega-3 registration initiated in FY2024 (market not specified)—FY2024–25—FY2024 Appendix 4E
Water-soluble vitamin D platformPatent filed in 2019 for a platform making fat-soluble actives water-soluble; management claimed up to 80x better absorption (unvalidated)ConsumersPlanned 2021—NutraIngredients-Asia, May 2021
Emulin M / Emulin CProducts previously listed on the Australian Register of Therapeutic Goods (ARTG 300145, 300147); listings cancelled under s30(2)(f)—Cancelled—TGA

Distribution: one external distributor handles 92% of Supplements revenue. Online sales via Holista-owned webstores (Alterni.com, Holista.global) are noted in the 11 September 2025 counterfeit-product announcement.

Ovine Collagen

ProductDescription & capabilitiesTarget customerStatusPricingSource
Ovine collagen (cosmetic grade, 300 kDa intact)Collagen extracted from disease-free Australian sheep using patented methods; halal-certified; positioned as an alternative to bovine/porcine collagen (avoids BSE concerns, culturally acceptable)Cosmetic manufacturers (one customer = 100% of segment revenue)Legacy Collie plant ceased in late 2024; sales drawn from existing stock—FY2025 Annual Report; Regenerex press release, Sep 2025
Nano-collagen (medical)Patented/patent-pending nano-collagen for chronic wound care; IP filings underwayRegenerex Pharma (exclusive worldwide wound-care rights)Pre-commercial; first Regenerex order US$51,700 received 24 Dec 2025Minimum purchase commitments: US$50k (2025), US$3m (2026), US$6m (2027), US$9m p.a. from 20281H FY2025 Interim Report; Appendix 4C Jan 2026
Ovine exosomesResearch programme commenced 2023ResearchEarly-stage—1H FY2023 Half Year Review

Food Ingredients

ProductDescriptionTarget customerStatusSource
Low-GI bread premix (incl. GI Lite™)Lowers the glycaemic index of baked goods without changing taste or mouthfeel; adopted by Costanzo's Bakery (US) in 2020Bakeries and QSR chainsFY2025 segment revenue −49.7%FY2021 4E; FY2025 Annual Report
Low-GI noodles/pasta and flatbreadsLow-GI formulationsNoodle and flatbread manufacturersActiveFY2025 Annual Report
Low-calorie / low-GI sugar substituteSugar reduction ingredientF&B manufacturersActiveFY2025 Annual Report
Reduced-sodium salt and low-fat frying solutionsEarlier suite (reduced-sodium salts, low-fat fried foods)F&B manufacturersCurrent status not disclosedASX release, 12 May 2020
Healthier croissant (Berjaya Country Farms / Starbucks Malaysia)Healthier croissant formulation; first commercial order announcedCafé chainsHistorical (c.2021–22)Stocklight register; FY2021 4E
Post-biotic nutritionUnder evaluation—DevelopmentFY2025 Annual Report Outlook

Infection Control / Agriculture

ProductDescriptionStatusSource
NatShield™ sanitiserAlcohol-free, plant-based sanitiser using Path-Away®; tested >99.99% against a COVID-19 surrogate (feline coronavirus). Subject of ASIC misleading-statement findingsSegment revenue negligible since 2022ASIC 21-202MR; ACN Newswire
Nano silver disinfectantAll-natural disinfectant (test results announced)Status not disclosedStocklight register
"List N" disinfectant (US)US EPA List N disinfectant launch announced December 2020Status not disclosedASX announcement 11 Dec 2020
Nano ureaAgricultural nano-fertiliserPilot-to-recurring orders: 1H FY2026 sales A$23,484 (with probiotics)1H FY2026 Half Year Review
Nano copperAgricultural nano-inputPilot orders FY2025FY2025 Annual Report
Poultry probioticsFeed probioticPilot orders FY2025; building in 2026FY2025 Annual Report; 1H FY2026
Odour management solutionsPlanned revenue lineExpected 2026FY2025 Annual Report Outlook

Financial Narrative

Data provenance. FY2024–FY2025 figures are from audited statements (FY2025 Annual Report). FY2021–FY2023 revenue and net loss are from company Appendix 4E commentary, cross-checked against TipRanks. FY2021–FY2023 pre-tax income is from TipRanks only.

Income statement — 5-year summary

Sources: FY2021 Appendix 4E (28 Feb 2022); FY2022 Appendix 4E (28 Feb 2023); FY2024 Appendix 4E (28 Feb 2025; FY2023 comparatives: revenue A$5,946,909, attributable loss A$4,805,763); FY2025 Annual Report. FY2021–FY2023 EPS computed from aggregator weighted average share counts (275.35m, 276.82m, 278.80m). FY2024 pre-tax figure is continuing operations only (A$68,573). Discrepancy: company commentary rounds the FY2021 net loss to A$1.3m and the FY2022 loss to A$1.5m; TipRanks shows A$1.26m and A$1.45m.

Revenue CAGR FY2021–FY2025: −7.9% p.a. (A$8.02m to A$5.76m).

Detailed income statement, FY2024–FY2025 (A$)

Source: FY2025 Annual Report, consolidated statement of profit or loss. Gross profit is computed as revenue less raw materials (net of inventory movements) less distribution costs, which reconciles to the company's stated gross margins of 42% (FY2024) and 45% (FY2025).

Commentary. The headline FY2025 loss of A$0.95m masks a materially improved operating core. Excluding the A$1.09m ASIC cost provision and approximately A$0.395m of ProImmune legal fees (FY2025 Annual Report), adjusted pre-tax profit would have been roughly +A$0.58m. That figure, however, still includes A$0.83m of credit-loss impairment reversals (debt recoveries, notably from related party iGalen Inc). Stripping both legal items and recoveries leaves an underlying pre-tax loss of approximately A$0.25m. This aligns with management's statement that Malaysian operations earned A$889,000 pre-tax, or approximately A$152,000 excluding non-recurring recoveries (FY2025 Chairman's Letter).

The 3-point gross margin expansion is attributed to ringgit strength, pricing discipline and cost control. Employee costs fell 17% and advertising fell 37%. FY2024's near-breakeven result was similarly flattered by A$1.29m of impairment reversals and recoveries, including A$560,000 from loans and A$534,000 from trade receivables (FY2024 Appendix 4E).

The structural inflection is therefore modest. Holista has moved from structurally loss-making (FY2020–FY2023) to approximately breakeven on an underlying basis. Recurring recoveries, which cannot persist indefinitely, have masked continued losses in Food Ingredients and Corporate.

Interim performance (A$)

Sources: 1H FY2025 Interim Report; 1H FY2026 Half Year Review. The 1H FY2026 net loss includes approximately A$2.66m of one-off costs from the ProImmune settlement. Excluding these, the company reports underlying profit after tax of approximately A$0.095m.

Quarterly trading, 2026 (A$)

Sources: Appendix 4C reports (30 Jan 2026, 28 Apr 2026, 30 Jul 2026). Q4 FY2025 total revenue and Q1 FY2026 net operating cash flow were not explicitly retrieved (zeros are placeholders); Q1 operating cash flow was described as a net outflow driven by inventory and legal fees. Q2 FY2026 operating outflow includes the US$1.0m initial ProImmune payment. Unused financing facilities stood at A$1.45m at 30 June 2026.

Balance sheet (A$)

Sources: FY2025 Annual Report; 1H FY2025 Interim Report. Total equity at 31 December 2023 was −A$3,386,159 (statement of changes in equity).

Debt composition (31 Dec 2025): current borrowings are predominantly Malaysian banker's acceptances (A$1.25m at 30 June 2025), plus a CIMB term loan secured over Malaysian freehold land and buildings (carrying value A$700,610) and small related-party loans. Cash of A$1.10m was held as term deposits. Security deposits of A$355,366 are restricted cash pledged to Malaysian banks (FY2025 Annual Report Notes 8, 13, 14, 18).

Commentary. FY2025 was a balance-sheet repair year. Equity raised totalled A$3.85m (A$1.55m convertible notes converted plus the A$2.295m placement), moving total equity from −A$3.37m to −A$0.42m and turning the group to net cash. The repair was immediately consumed in 2026: the US$1.8m ProImmune settlement (approximately A$2.66m expensed) and the A$1.09m ASIC costs claim (provided for in FY2025, still payable) exceed the year-end cash balance. Cash fell to A$526,000 by 30 June 2026, and the final US$800,000 instalment was paid in July 2026, partly funded by a A$370,724 convertible loan from Powerwind Plantation Sdn Bhd (ASX announcement, 17 July 2026).

The persistent negative NCI (−A$1.54m) indicates accumulated losses in partly owned subsidiaries; the subsidiaries involved are not identified in retrieved material.

Cash flow (A$)

Source: FY2025 Annual Report, consolidated statement of cash flows.

Commentary. Excluding the A$900,000 ASIC penalty instalment in each year, operating cash flow was approximately −A$114,000 in FY2024 and −A$626,000 in FY2025. FY2025 was affected by a A$290,000 inventory build and legal fees. Capex is negligible (A$23,353), so the business is asset-light, but it lacks the scale to self-fund the collagen strategy, which has been externalised to the Ovicoll JV partner. Banker's acceptance facilities roll over at roughly A$6m per year (gross borrowings and repayments), underscoring reliance on Malaysian trade finance.

Ratios

Computed from FY2025 Annual Report data. ROE, ROIC and debt/equity are not meaningful because equity is negative in both years (and attributable equity was only A$1.12m at end-FY2025). A full cash conversion cycle is not computable because payables include non-trade items (refund liabilities, ASIC provision); trade payables were A$1.84m at 30 June 2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey products/services

Supplements

Manufacture (via contract) and wholesale distribution of dietary supplements in Malaysia

PRISTIN® Omega-3 range, PROBIO-30, SKNPRO Collagen, other Total Health-branded supplements

Ovine Collagen

Manufacture and distribution of cosmetic-grade collagen; medical-grade/nano-collagen development

Ovine collagen (300 kDa intact), nano-collagen

Food Ingredients

Manufacture and wholesale distribution of healthy food ingredients

Low-GI premixes (bread, noodles, flatbread), sugar substitute, reduced-sodium and reduced-fat solutions

Infection Control / Agriculture

Natural sanitisers (legacy) and agricultural biotechnology (new)

NatShield and natural disinfectants; nano urea, nano copper, poultry probiotics

Corporate

Head office, listing and legal costs

—

Segment revenue (AUD)

Segment revenue (AUD)FY2024FY2025

Supplements

4,686,9635,222,652

Ovine Collagen

148,290148,529

Food Ingredients

762,974383,464

Infection Control / Agriculture

129,410

Total external revenue

5,598,2395,764,055

Revenue by Segment (AUD)

Segment PBT (AUD)FY2024FY2025

Supplements

118,767772,615

Ovine Collagen

-219,95216,287

Food Ingredients

-441,063-347,543

Infection Control / Agriculture

560,077780,474

Corporate

66,599-2,130,380

Group PBT (continuing)

-84,428-908,547

Segment Revenue

SegmentFY2025 revenue growth YoY (%)FY2025 PBT margin (%)FY2024 contribution (%)FY2025 contribution (%)

Supplements

11.414.883.790.6

Ovine Collagen

0.211.02.62.6

Food Ingredients

-49.7-90.613.66.7

Infection Control / Agriculture

——0.00.2

Interim segment revenue (AUD)

Interim segment revenue (AUD)1H FY20241H FY20251H FY2026

Supplements

2,186,5322,593,8772,910,000

Ovine Collagen

46,54090,3940

Food Ingredients

428,292204,8890

Infection Control / Agriculture

12023,484

Total revenue

2,661,3762,889,1602,990,000

Segment Overview — Supplements

SegmentTotal assetsTotal liabilitiesNet assets/(liabilities)

Supplements

3,102,790-2,854,542248,248

Ovine Collagen

68,534-1,597,720-1,529,186

Food Ingredients

2,613,017-4,520,826-1,907,809

Infection Control / Agriculture

1,246-352,446-351,200

Corporate (incl. eliminations)

87,8473,304,0293,121,879

Group

5,873,435-6,291,503-418,068

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (AUD Mn)

8.028.245.955.605.76

Revenue growth YoY (%)

12.92.7-27.8-5.93.0

Pre-tax income (AUD Mn)

-1.20-1.36-4.850.07-0.91

Net income attributable (AUD Mn)

-1.26-1.45-4.81-0.08-0.95

Net margin (%)

-15.7-17.6-80.8-1.5-16.5

Basic/diluted EPS (A$ cents)

-0.46-0.52-1.72-0.03-0.29

Dividends per share (A$ cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement (AUD)

Line item (AUD)FY2024FY2025

Revenue from contracts with customers

5,598,2395,764,055

Other income

65,41026,756

Raw materials and consumables (net of inventory change)

-2,782,867-2,781,725

Distribution and other costs of sales

-441,292-372,124

Gross profit (company definition)

2,374,0802,610,206

Advertising and promotion

-405,574-254,156

Consultancy and professional fees

-98,432-517,922

Employee benefits

-2,152,019-1,785,964

Research and development

-72,064-36,066

Impairment reversal / (expense), net

1,286,394829,569

Foreign exchange gain / (loss)

-165,16814,570

Other expenses

-509,574-544,123

ASIC litigation provision

0-1,090,000

Share-based payments

-33,4790

EBITDA (computed)

289,574-747,130

Depreciation and amortisation

-101,553-53,989

EBIT / operating income (computed)

188,021-801,119

Finance costs

-119,448-107,428

Profit / (loss) before tax (continuing)

68,573-908,547

Income tax expense

-171,579-42,834

Discontinued operations

15,8550

Net loss

-87,151-951,381

Attributable to owners

-84,214-948,921

Margin (%)

Margin (%)FY2024FY2025

Gross margin

42.445.3

EBITDA margin

5.2-13.0

Operating (EBIT) margin

3.4-13.9

Pre-tax margin

1.2-15.8

Net margin

-1.5-16.5

Income Statement (AUD) and Margin Analysis (%)

Metric (AUD)1H FY20241H FY20251H FY2026

Revenue

2,661,3762,889,1602,990,000

Gross margin (%)

4241.944.3

Profit / (loss) before tax

-907,141-277,1950

Net loss after tax

-981,568-296,569-2,560,000

Basic EPS (A$ cents)

-0.35-0.090

Cash Flow (AUD)

Metric (AUD)Q4 FY2025Q1 FY2026Q2 FY2026

Revenue

01,490,0001,500,000

Customer receipts

1,700,0001,310,0001,480,000

Net operating cash flow

238,0000-1,290,000

Closing cash

2,160,7711,944,000526,000

Balance Sheet (AUD)

Line item (AUD)31 Dec 202430 Jun 202531 Dec 2025

Cash and cash equivalents

21,72041,7472,160,771

Trade and other receivables

1,031,049960,145950,606

Inventories

810,086818,0301,099,817

Total current assets

2,559,5132,792,0115,112,047

Property, plant and equipment

746,263734,994741,038

Goodwill and intangibles

14,0527,8755,989

Total assets

3,341,8943,553,0555,873,435

Trade and other payables

4,333,9673,452,9334,434,150

Borrowings — current

1,314,8261,302,0231,166,799

Borrowings — non-current

428,525415,230404,094

Total borrowings

1,743,3511,717,2531,570,893

Net debt / (net cash)

1,721,6311,675,506-589,878

Total current liabilities

6,264,6345,219,1225,880,895

Total liabilities

6,709,6145,647,0826,291,503

Working capital

-3,705,121-2,427,111-768,848

Equity attributable to owners

-1,729,404-528,5281,119,389

Non-controlling interest

-1,638,316-1,565,499-1,537,457

Total equity

-3,367,720-2,094,027-418,068

Cash Flow (AUD) (Annual)

Line item (AUD)FY2024FY2025

Receipts from customers

6,625,8395,844,498

Payments to suppliers and employees

-6,445,800-6,372,371

ASIC penalty and related costs

-900,000-900,000

Operating cash flow

-1,013,745-1,526,003

Capex (PP&E)

-7,040-23,353

Free cash flow (OCF − capex)

-1,020,785-1,549,356

Net investing cash flow

692,118-176,359

Proceeds from share issues

03,847,381

Net borrowings / (repayments)

377,547-191,830

Net financing cash flow

-143,7543,647,786

Dividends paid

00

Share buybacks

00

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROA (%, net loss / average assets)

-2.6-20.6

Current ratio (x)

0.410.87

Net debt / EBITDA (x)

5.9—

Interest coverage (EBIT / finance costs, x)

1.6-7.5

Asset turnover (x)

1.571.25

Inventory days (on raw materials consumed)

104131

Region revenue (AUD)

Region revenue (AUD)FY2024FY2025

Malaysia

5,449,9495,615,526

Australia

148,290148,529

United States

00

Total

5,598,2395,764,055

Revenue by Region (%)

Region (%)FY2025 growth YoY (%)FY2025 share (%)

Malaysia

3.097.4

Australia

0.22.6

Revenue by Region (AUD)

Region PBT (AUD)FY2024FY2025

Australia

-513,250-1,795,490

Malaysia

794889,405

United States

428,028-2,462

Group

-84,428-908,547

Share price metric (AUD)

Share price metric (AUD)202420252026 YTD

Opening price

0.0130.0130.086

Closing / latest price

0.0130.0860.067

Period change (%)

0561.5-22.1

Period high

0.020.110.089

Period low

0.010.0130.05

Share Price & Returns

HorizonApproximate returnNote

1-year

~−20% (from ~A$0.08–0.09 in October 2025 to ~A$0.067)

Approximate

Valuation Snapshot

MetricValueBasis

Market capitalisation

~A$24.6m

Price × shares

Enterprise value

~A$25.7m

Market cap + FY2025 borrowings (A$1.57m) − 30 Jun 2026 cash (A$0.53m); mixed-date approximation

EV / Sales (TTM)

~4.4x

TTM revenue A$5.87m (FY2025 − 1H FY2025 + 1H FY2026)

Capital Markets

ItemStatus

Analyst consensus

None; no broker coverage identified

Dividends

None paid or declared in FY2024, FY2025 or 1H FY2026; no dividend policy

Credit ratings (Moody's, S&P, Fitch)

Not rated

Debt maturity profile

Current borrowings A$1.17m (banker's acceptances, rolling); non-current A$0.40m (CIMB term loan, secured); Powerwind convertible loan A$370,724 (2026; terms not fully verified)

Options / performance rights

None outstanding at the FY2025 report date

Analyst Conclusions

Management outlook (FY2025 Annual Report and 2026 releases)

Management expects to maintain operational discipline and cost control. Specific expectations are:

  • Continued ringgit strength supporting AUD-translated revenue.

  • The Collie plant commencing operations in 2H 2026 (targeted December 2026 per the June 2026 announcement), subject to funding and execution.

  • Possible initial revenue from agricultural biotechnology and odour management in 2026.

No quantitative earnings guidance has been given. There is no consensus.

Bull case

  1. Regenerex scales. Even 50% of the 2027 minimum commitment (US$6m) would roughly add revenue equal to current group revenue at likely high margins. This would transform Holista from a Malaysian distributor into a medical collagen supplier.

  2. Underlying breakeven is real. 1H FY2026 underlying profit after tax of ~A$0.095m, a 44% gross margin and 12% Supplements growth suggest the core can self-fund once legal costs end. ProImmune is now closed and the ASIC penalty is paid.

  3. Capital-light optionality. SCC funds Ovicoll, Holista receives an 8% royalty plus a path to 75% ownership, and existing shareholders retain IP upside without bearing capex.

Bear case

  1. Liquidity is precarious. Cash of A$526,000 at 30 June 2026, the final US$800,000 settlement payment in July and the unpaid ~A$1.09m ASIC costs claim make a dilutive raise likely in the near term, at a share price ~4x below the 2025 high-water mark of A$0.11.

  2. Concentration risk is extreme. About 83% of revenue flows through one Malaysian distributor; loss or renegotiation of that contract would remove most of the business. FY2024's pharmacy-chain returns show how fragile the channel is.

  3. Collagen promises carry a credibility discount. There is no shortfall penalty in the Regenerex contract, and the 2026 minimum looks unattainable against orders of US$51,700 to date. Regenerex is a related party and a small OTC company. Holista's disclosure history includes court-found misleading statements, and collagen revenue has been ~A$0.15m per year.

Catalysts and monitorables (next 12 months)

TimingCatalyst
By 31 Oct 2026Q3 FY2026 Appendix 4C: cash after the final ProImmune payment; any capital raise
Q4 2026Resolution or payment terms of the ASIC costs claim
Dec 2026Ovicoll Collie plant commissioning
Through 2026–27Regenerex order flow against the US$3m 2026 minimum; any FDA submissions
Feb–Mar 2027FY2026 Appendix 4E and Annual Report; going-concern status
OngoingSupplements growth versus MYR moves; distributor contract status; agriculture order conversion
OngoingConversion of the Powerwind loan; changes in substantial holdings (Neo Health, SCC-linked parties)

Analyst verdict

Holista Colltech is best understood as two businesses sharing one listing.

The first is a modest but genuinely improving Malaysian supplements distributor. PRISTIN remains a credible premium halal brand, gross margins have expanded to the mid-40s, and the Malaysian operations produced an underlying pre-tax profit in FY2025 for the first time in several years. Management's cost discipline is visible: KMP pay fell by two-thirds, employee costs fell 17%, and the CEO works for a nominal A$1. On an underlying basis the business is near breakeven, a meaningful improvement on the A$1–5m annual losses of FY2020–FY2023.

The second is an option portfolio around ovine and nano-collagen. Its value depends almost entirely on two partners: Regenerex, a related-party OTC company with no penalty for missing its minimum purchases, and Swang Chai Chuan, which funds the Collie plant in exchange for half the JV. The structure is sensibly capital-light. However, the gap between contracted minimums (US$3m in 2026) and actual orders (US$51,700) is large, and the plant does not yet exist.

The balance sheet is the binding constraint. Legal legacies have consumed approximately A$4.5m+ in penalties, settlements and provisions since 2024, wiping out the equity rebuilt through the 2025 raisings. With A$526,000 of cash at June 2026 and the ASIC costs claim outstanding, further dilution appears likely, and the auditor continues to flag a material uncertainty over going concern.

At roughly A$25m market capitalisation (about 4x trailing sales), the market already prices significant collagen success into a business whose provable earnings power is close to zero. Governance has improved since 2024, with an independent chair and a refreshed board, but committee functions remain undifferentiated, D&O insurance is absent, and key contracts are with related parties.

**Verdict: speculative, high-risk. Until those are visible, the asymmetry favours caution.


All figures in A$ unless stated. "Not publicly disclosed" denotes information not found in company filings or reliable public sources as of 10 October 2026. Aggregator-derived and approximate figures are labelled.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundQualificationsShares held (31 Dec 2025)

Lai Kwok Kin

Independent Non-Executive Chairman

Director 2024 (FY2024 fees shown); Chairman 24 Apr 2025

~40 years in journalism (Reuters Chief Correspondent, Malaysia & Brunei), equity research (Merrill Lynch head of Malaysia research), and investor relations/crisis communications; founded WeR1 group in 1999

BA (Arts & Social Science), National University of Singapore; postgraduate diploma in Journalism, City University of London

9,675,785

Leong Man Loong

Executive Director and CEO

Interim CEO 3 Jan 2025; CEO 3 Jul 2025

Entrepreneur and inventor with ~30 years in nanotechnology, green chemistry and environmental technology; Executive Chairman of the SHEPROS Group (Malaysia)

BSc Mechanical Engineering (US)

36,159,845

Gregory Pilant

Non-Executive Director (non-independent)

26 Mar 2025

Founder, CEO and Chairman of Regenerex Pharma (OTC: RGPX); founded Greystone Pharmaceuticals; led Stanley Pharmaceuticals, National Labs and MedStat; 30+ years in wound care

Not disclosed (University of Memphis Business Hall of Fame inductee)

30,234,317

Robert Gemelli

Independent Non-Executive Director

14 May 2025

Perth-based entrepreneur: insurance (Federation Insurance), entertainment (GM, Entertainment Enterprises; own business in Broome); active ASX investor

—8,715,016

Sam Yee (Yee Yuen Keong)

Independent Non-Executive Director

14 May 2025

Melbourne consultant; former CEO, Gribbles Diagnostic; senior roles at Wyeth, Pfizer (Asia Pacific Marketing Director), Merck Serono, GSK and Roche

B.Pharm (University of Wales); MBA (University of Strathclyde)

10,000

Jay Stephenson

Company Secretary

1 Sep 2021

30+ years in business development; CFO/Company Secretary roles; NED of Liberty Metals and Pinnacle Minerals

——

“—” = not publicly disclosed.

Directors' Remuneration

KMPFY2025 total (AUD)FY2024 total (AUD)

Lai Kwok Kin

48,00037,677

David Deloub (former Chairman, to 16 Apr 2025)

22,50060,000

Loren King (former NED, to 16 Apr 2025)

18,00048,000

Robert Gemelli

15,0000

Sam Yee

15,0000

Leong Man Loong (CEO)

00

Gregory Pilant

00

Rajen Manicka (director to 19 Mar 2024, then consultant)

0224,635

Total KMP

118,500370,312

Board & Management Changes

DateChange

19 Mar 2024

Dr Rajen Manicka disqualified for 4 years; ceases as director (consulting thereafter, not KMP in FY2025)

3 Jan 2025

Leong Man Loong appointed Executive Director and Interim CEO

26 Mar 2025

Gregory Pilant appointed NED

16 Apr 2025

David Deloub (Chairman) and Loren King (NED) resign

24 Apr 2025

Lai Kwok Kin becomes Independent Chairman

14 May 2025

Robert Gemelli and Sam Yee appointed independent NEDs

3 Jul 2025

Leong confirmed as CEO

Major Shareholders

HolderShares% (approx.)BasisSource

Galen Biomedical Inc

58,514,245

20.99 (of ~279m shares at the time)

—

MarketIndex

Leong Man Loong (CEO)

36,159,8459.8

Director interest

FY2025 Annual Report

Gregory Pilant

30,234,3178.2

Director interest

FY2025 Annual Report

Neo Health Sdn Bhd

23,467,7566.38

Substantial holder notice, 11 Nov 2025

Form 603, 13 Nov 2025

Lai Kwok Kin

9,675,7852.6

Director interest

FY2025 Annual Report

Robert Gemelli

8,715,0162.4

Director interest

FY2025 Annual Report

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs Holista

Supplements (Malaysia)

Blackmores (Kirin Holdings)

Larger multi-category brand with strong pharmacy presence

Supplements (Malaysia)

Kotra Pharma (Appeton)

Local listed peer with broader consumer health range

Supplements (Malaysia)

VitaHealth

Local supplement brand in pharmacy channel

Supplements (Malaysia)

Scott's (Haleon)

Mass-market fish oil/cod liver oil

Supplements (Malaysia)

Nutrilite (Amway), Herbalife

Direct-selling scale players

Supplements (Malaysia)

Watsons / Guardian private labels

Low-price fish oil (RM19.90 vs PRISTIN RM67.60 in 2021 trade press)

Collagen (ingredients)

Rousselot (Darling Ingredients)

Global bovine/porcine/marine collagen leader

Collagen (ingredients)

Gelita

Global collagen peptides leader

Collagen (ingredients)

Nitta Gelatin

Japanese collagen/gelatin producer

Collagen (ingredients)

PB Leiner (Tessenderlo)

Gelatin and collagen peptides

Collagen (medical / wound care)

Integra LifeSciences

Collagen-based regenerative wound products

Collagen (medical / wound care)

Smith+Nephew

Advanced wound management

Food ingredients (sugar/GI reduction)

Tate & Lyle, Ingredion, Cargill, Roquette

Global specialty ingredient majors

Peer Comparison FY2025

CompanyLatest annual revenue (approx.)Revenue growthMargin profileR&D intensity

Holista Colltech (FY2025)

A$5.76m

3.0%

GM 45%; net −16.5%

0.6%

Recent Developments

Discrepancy: * the 1H FY2026 review dates the final ProImmune payment to 10 July 2026, while the separate ASX announcement reporting it is dated 17 July 2026.

The Q3 FY2026 Appendix 4C is due by 31 October 2026.

Company Snapshot

$3.7M

Revenue

1995

Founded

Subiaco, Australia

Headquarters

SWOT Analysis

Strengths

  • Profitable core franchise: Supplements earned A$772,615 segment PBT on A$5.22m revenue in FY2025, a 14.8% margin (FY2025 Annual Report Note 3).
  • Margin expansion: group gross margin rose to 45% in FY2025 (42% in FY2024) and reached 44.3% in 1H FY2026.
  • Durable brand and halal positioning: PRISTIN is halal-certified and premium-priced, selling at roughly 3.4x a low-cost rival in 2021 trade-press comparisons.
  • Unique collagen IP: management positions Holista as the only producer of collagen from disease-free Australian sheep using patented methods; nano-collagen patent filed May 2023.
  • Cost-light leadership: CEO paid A$1 p.a.; total KMP remuneration A$118,500 in FY2025, down from A$370,312.
  • Externally funded growth projects: SCC funds Ovicoll (RM5m) and Regenerex funds clinical trials, minimising Holista's capex.

Weaknesses

  • Extreme customer concentration: one distributor accounts for 92% of Supplements revenue (~83% of group).
  • Weak balance sheet: total equity −A$418,068 at end-FY2025; working capital deficit A$768,848; going-concern material uncertainty flagged by the auditor in both 1H FY2025 and FY2025.
  • Low-quality earnings: FY2024 and FY2025 results were supported by A$1.29m and A$0.83m of impairment reversals and recoveries respectively.
  • Tight liquidity: cash of A$526,000 at 30 June 2026 against A$1.45m unused facilities and an outstanding ASIC costs claim.
  • Negligible R&D: A$36,066 in FY2025 (0.6% of revenue), inconsistent with the biotech positioning.
  • No collagen manufacturing capacity: since the Collie plant closed in late 2024, collagen sales have been drawn from existing stock.

Opportunities

  • Regenerex minimum commitments: US$3m (2026) to US$9m p.a. (2028+), each multiples of current non-supplement revenue.
  • Ovicoll royalty: 8% of JV gross sales to Holista, plus an option to lift its stake to 75% over five years.
  • Agricultural biotech: 1H FY2026 sales of A$23,484 moving from trials toward recurring orders.
  • Digital channels: marketplace expansion helped drive Supplements +12.2% in 1H FY2026.
  • Currency tailwind: management expects continued ringgit strength to support AUD-reported revenue in 2026.
  • Strategic shareholders: Neo Health (6.38%) and SCC (via the JV) could provide capital and distribution in Asia.

Threats

  • Regenerex counterparty risk: no shortfall penalties; Regenerex is a small OTC-listed company; Holista itself flags the risk to projected cash flows.
  • ASIC costs claim: ~A$1.09m sought (December 2025), against A$526,000 of cash at mid-2026.
  • Dilution: the Q2 FY2026 4C explicitly contemplates further capital raising; the Powerwind loan is convertible.
  • Counterfeiting: counterfeit PRISTIN sold on e-commerce platforms (police report September 2025).
  • Regulatory compliance: Emulin ARTG listings cancelled; supplement registrations required in each market.
  • FX reversal: with 97% of revenue in MYR, a weaker ringgit would directly cut reported revenue.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025Chairman Deloub and NED King resignBoard renewal begins
17 Apr 2025Late director's interest notice addressed; unquoted securities issuedMinor compliance issue
24 Apr 2025Lai Kwok Kin appointed ChairmanGovernance reset
28 Apr 2025ProImmune files WA enforcement proceedings; Holista notes resolution of ASIC matterLitigation escalates
14 May 2025Gemelli and Yee join as independent NEDsBoard independence improved
26–29 May 2025Collie operations ceased; strategic pivot to nano-collagen; licensing discussions updateBusiness model shift
3 Jul 2025Leong Man Loong confirmed CEO at A$1 p.a.Founder-style alignment, low cost
Jul 2025Q2 FY2025 4C: Supplements +38% QoQ; customer receipts A$1.65mOperating momentum
31 Jul 2025RM1.0m debt recovery from iGalen Inc; Regenerex licensing announced (US)Cash and earnings support
26 Aug 2025Binding Regenerex supply agreementKey growth catalyst
29 Aug 20251H FY2025: revenue +8.6%, net loss −69.9%Improving trend
11 Sep 2025Counterfeit PRISTIN police reportBrand protection risk
30 Oct 2025A$2.295m placement at A$0.07Liquidity repair
11–13 Nov 2025Neo Health Sdn Bhd becomes substantial holder (6.38%)New strategic investor
13 Nov 2025WA court hears ProImmune summary judgment applicationLitigation risk
Dec 2025ASIC seeks ~A$1.09m legal costsUnexpected liability; shares fell ~8% on the day per Stocklight
24 Dec 2025First Regenerex order (US$51,700)Contract activated
30 Jan 2026Q4 FY2025 4C: positive operating cash flow A$238,000First positive quarter in the period
27 Feb 2026FY2025 Appendix 4ERevenue +3%, loss A$0.95m
30 Mar 2026FY2025 Annual Report and Appendix 4GGoing-concern material uncertainty
7 Apr 2026WA Supreme Court summary judgment for ProImmuneAdverse legal outcome
8–10 Apr 2026Trading halt, then suspensionDisclosure process
22 Apr 2026US$1.8m settlement; reinstatementRemoves uncertainty at a cost
28 Apr 2026Q1 FY2026 4C: revenue ~A$1.49m; cash A$1.944mStable trading
5 May 2026Ovicoll JV with Swang Chai ChuanCollagen capacity funded externally
25 May 2026AGM held; results of meeting releasedRoutine
18–19 Jun 2026Ovicoll acquires Collie siteExecution milestone
9 Jul 2026Powerwind convertible loan term sheet (A$370,724)Bridge financing
10–17 Jul 2026Final US$800,000 ProImmune paymentLitigation closed
30 Jul 2026Q2 FY2026 4C: revenue A$1.50m; cash A$526,000; A$1.45m unused facilities; capital raising flagged as possibleLiquidity tight
31 Aug 20261H FY2026: revenue +3.6%, gross margin 44.3%, net loss A$2.56m (A$2.66m one-off)Underlying breakeven

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement (AUD): Revenue from contracts with customers to Employee benefits: Revenue from contracts with customers rose from AUD 5,598,239 in FY2024 to AUD 5,764,055 in FY2025.
Holista CollTech Limited — Income Statement (AUD): Revenue from contracts with customers to Employee benefits
Series (AUD)FY2024FY2025
Revenue from contracts with customers5,598,2395,764,055
Other income65,41026,756
Raw materials and consumables (net of inventory change)-2,782,867-2,781,725
Distribution and other costs of sales-441,292-372,124
Gross profit (company definition)2,374,0802,610,206
Advertising and promotion-405,574-254,156
Consultancy and professional fees-98,432-517,922
Employee benefits-2,152,019-1,785,964

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.